Trajectories of neurodegeneration in body- and brain-first subtypes of Lewy body disease. In body-first patients (top panel) the sympathetic innervation of the heart starts to degenerate 15-20 years before diagnosis. Prodromal patients with isolated RBD (iRBD) nearly all have severe cardiac denervation (invisble heart), but a normal or near-normal dopamine scan of the brain. When diagnosed with PD, these patients typically have a dopamine scan with rather symmetric loss in the putamen and an invisible heart. In brain-first patients (bottom panel), the dopamine system starts to degenerate early. At the time of PD diagosis, these patients often shown quite asymmetric dopamine loss in the putamen, but most patients still have a normal or near-normal heart scan. A few years later, brain-first patients will start to show loss of the cardiac sympathetic innervation.

file_download Download in HQ

Related content

image Image Graphic showing extracellular, multimerization, and intracellular targets of alpha-synuclein for therapeutic intervention in Parkinson’s disease
Possible α-synuclein targets for development of therapies for Parkinson’s disease

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

26.06.2025 Parkinson’s Disease
image Image Chart showing progression of functional decline in Parkinson’s disease with different treatment approaches, from symptomatic benefit to disease modification.
Disease modification in Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

26.06.2025 Parkinson’s Disease
image Image Diagram showing how COMT inhibitors block the conversion of L-DOPA to 3-OMD, enhancing dopamine levels in the synapse in Parkinson’s disease.
Catechol-O-methyltransferase (COMT) inhibitors mechanism of action

Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA

26.06.2025 Parkinson’s Disease